Abstract Background The addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery in an earlier analysis of this phase 3 trial […]
pembrolizumab
Data further support pembrolizumab regimen for early triple-negative breast cancer
December 09, 2021 2 min read Source/Disclosures Published by: Source: Schmid P, et al. Abstract GS1-01. Presented at: San Antonio Breast Cancer Symposium (virtual meeting); Dec. 7-10, 2021. Disclosures: Merck Sharp & Dohme, a subsidiary of Merck & Co. Inc., provided funding for this study. Schmid reports […]